Hanmi/Aptose’s AML Contender Shows Early Promise
Oral Myeloid Kinome Inhibitor Set For Expansion Trials
Executive Summary
Hanmi Pharmaceutical’s hopes for AML drug candidate HM43239, licensed out to Aptose Biosciences, are rising amid accumulating clinical data that appear to put the oral myeloid kinome inhibitor on the right track to registrational studies.
You may also be interested in...
SK Bioscience First To Line In Korea COVID Vaccine Race
SK Bioscience has received the world’s first approval of its in-house developed recombinant protein COVID-19 vaccine SKYCovione (GBP510), in its home market of South Korea, two years after it began development. Strong support from the domestic government and international cooperation helped pave the way.
Korea’s First Home-Grown COVID-19 Vaccine To Speed Hub Ambitions
Only one last step remains before the approval of South Korea’s first home-grown COVID-19 vaccine as SK Bioscience’s SKYCovione (GBP510) receives positive assessments from review committees. Any nod, which could happen this week, would mark a milestone for the country's ambitions of becoming a global vaccine hub.
China Rush Over? Korean Firms Step Up To Seize Opportunities
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.